• Teaser
  • Kapseln
  • Teaser
  • Teaser

GMP Chitosan, medical device chitosan, pure chitin, pharma chitosan, chitosan derivatives, GMP, Quality, producer | Heppe Medical Chitosan

Microfluidics for the production of chitosan-TPP nanoparticles

Microfluidics can precisely control the physiochemical properties of nanoparticles by mixing to the nanoliter. For this reason, nanoparticles for the transport of peptide drugs are to be developed in the study presented here with the help of chitosan from Heppe Medical Chitosan GmbH.

3D bio-printed chitosan networks for dental applications

Dental, bacterial diseases such as periodontitis can lead to tooth and bone loss. In the study presented here, chitosan, gelatine and Scutellariae baicalensis radix were combined to form a hydrogel to produce an anti-inflammatory implant using 3D bioprinting.

Cisplatin Chitosan microparticles to prevent recurrent breast cancer

Breast cancer is the most common type of cancer in women. In order to prevent the occurrence of metastases and the recurrence of tumors, a hydrogel breast implant loaded with cisplatin chitosan microparticles is to be produced in the presented study.

Chitosan nanoparticles to enhance the effect of anticancer drugs

Cancer is difficult to treat due to its early immune invasion and metastasis. In the study presented here, the frequently used chemotherapeutic drugs 5-flourouracil and cisplatin are encapsulated in TPP cross-linked chitosan nanoparticles and their in vitro anti-cancer effect is investigated.

Chitosan in polymer-based nanoparticles for drug delivery to the eye

Eye diseases are difficult to treat due to natural factors such as the blood-eye barrier, cornea or tear film. Polymer-based nanoparticles made of chitosan, among others, can help there to improve drug transport. In this article we would like to summarize a review on this topic.

Press release mRNA active ingredients: Protected for an optimized effect

Berlin, Halle, 16.03.2023: Since January of this year, the project "Zielwirk" is developing a new chitosan technology for the efficient release of mRNA active ingredients. The technology aims to ensure that drugs for the treatment of serious diseases can be better absorbed as well as processed by the body. The participating project partners Heppe Medical Chitosan GmbH, FDX Fluid Dynamix GmbH, Martin Luther University Halle-Wittenberg and the Fraunhofer Institute for Production Systems and Design Technology (IPK) are funded by the German Federal Ministry of Economics and Climate Protection (BMWK) with six million euros over three years.

Arginine-chitosan nanoparticles for siRNA transport

Small interfering RNAs (siRNAs) can be used as in gene therapies for e.g. cancers such as leukemia. However, the application of these is limited by a lack of efficient drug delivery. Therefore, in the presented study, chitosan was functionalized with arginine to form nanoparticles, loaded with siRNA, and their properties as siRNA vectors were investigated.

How chitosan can help against breast cancer

Breast cancer will affect one in eight women during their lifetime. Especially metastatic breast cancer has a low survival rate. In this article, we present a review of current research on the use of chitosan in breast cancer therapy and diagnostics.

Chitosan Reviews in 2021

A large number of reviews on Chitosan were also published in 2021. According to HMC searches in the PubMed database, a total of 181 new reviews with chitosan in the title appeared in 2021. In this article, we would like to give you an overview of the publications, as well as briefly introduce five reviews on various topics related to chitosan. Have fun reading!

Chitosan in endometriosis pain treatment

Chronic, painful diseases such as endometriosis can lead to a severe reduction in the quality of life of those affected. Drug delivery systems, such as chitosan-containing hydrogels, could enable efficient pain management with prolonged and targeted drug release. Therefore, in the study presented here, hydrogels made of chitosan and the vanillin derivative 2-hydroxy-5-nitrobenzaldehyde were investigated as a drug delivery system for diclofenac sodium salt.

Beta blockers and chitosan

Due to its biocompatibility and ability to increase the water solubility of drugs, chitosan can be used as an excipient in drug delivery systems. In the following article, we present the influence of physical mixtures of the beta-blocker carvediol (CVD) and chitosan on CVD solubility and release profile.

Chitosan for vaccine development against SARS-CoV-2

The global spread of SARS-CoV-2 can only be contained through vaccine development. Vector vaccines (DNA and viral) can be produced rapidly and inexpensively with current synthesis technologies. Challenges with DNA vaccines include degradation by DNases, inefficient uptake by antigen-presenting cells, and low immunogenicity. The Quil-A-loaded chitosan particulate adjuvant system (QAC) enables transport of plasmid DNA directly to target cells and delayed release over time. Here, we present two recent studies about chitosan-based delivery systems for vaccines.

Water-soluble drug release by chitosan microparticles

Chitosan and chitosan derivatives are promising biopolymers for nasal or vaginal drug delivery using micro- or nanoparticles. However, the pH-dependent solubility of chitosan and excessive water uptake in the presence of ions is suboptimal. Water uptake can result in rapid initial release of the drug due to collapse of the chitosan-based transport vehicle. To stabilize the drug release, research is being conducted to modify the polymer structure by physical crosslinking. Aim of the presented study was to investigate the influence of microparticle composition, in particular the amount of ion crosslinker (CF) introduced, on the release profile of water-soluble drugs from the chitosan matrix.

Chitosan implants for regenerative medicine

In recent decades, there have been major advances in regenerative medicine, such as the treatment of severe nerve injuries. Implants used as scaffolds for nerve cell regeneration are often made of biodegradable polymers, such as chitosan. Below, we present a study that investigated the degradation and stability of tubular chitosan-based implants.

Chitosan as adjuvant for vaccines

Adjuvants in vaccines are potent enhancers, which ensure that even small amounts of pathogens induce a permanent immune response. They are particularly necessary for inactivated vaccines and vaccines with antigen subunits. Several studies investigated chitosan as an adjuvant or antigen delivery system in various formulations (gels, aqueous dispersion, micro- and nanoparticles).

Publications with chitosan and chitosan derivatives by HMC in 2018

Worldwide, our chitosan and chitosan derivatives are used in research. We created a list of scientific articles published in 2018 using chitosan from HMC. Nanoparticles from chitosan or chitosan derivatives were most frequently produced and tested for a wide variety of applications, mainly directed drug delivery and tissue engineering. Curious where to find chitosan by HMC in research?

Drug delivery systems with chitosan

Biological barriers can limit the availability of a therapeutic agent in the target tissue. Drug delivery systems overcome these limitations to transport the correct dose of drug to its target site. The biopolymer chitosan has great potential for the development of innovative drug delivery systems. We present two articles that explore the treatment of cancer and noise-induced hearing loss with chitosan-based drug delivery systems.

Publications in March 2017 - antimicrobial activity of chitosan

In March 2017, 215 articles were released about chitosan and chitosan derivatives. The top three nations in chitosan research are China (59), India (32) and USA (27). Main focuses were nanoparticels, evaluation studies and pharmaceutical preparations.

Publications in July & August 2016 - drug delivery systems

Today´s topic is chitosan for drug delivery systems. In July and August 2016, 33 articles about chitosan combined with drug delivery systems were published. As might be expected, top publisher are China (13 articles), United States (5) and India (4). The articles investigated drug release by chitosan-based micro- or nanoparticles, hydrogels and nanocomposites. Thereby controlled release of cytostatics, proteins or peptides was mainly studied. (Source: www.gopubmed.org)

Publications in April 2016 - Tissue Engineering

In April 2016, 268 publications about chitosan were released. In addition to China (52) and the United States (25), Brazil (15) is on the third place of nations with the most publications. The following studies deal with chitosan as drug delivery system to support regeneration of dermal tissue or articular cartilage.

Publication May and June 2013

231 articles about chitosan and chitosan derivatives have been published in May and June 2013. The main topics focused on animal and human studies and on chitosan-based nanoparticles and pharmaceutical preparations. Moreover, the physico-chemical properties and pH sensitivity of various chitosan derivatives were intensively studied. Among the top nations of chitosan research are again: China (76 articles), USA (30) and India (14).

Publications in March and April 2014

In March and April, 234 publications were released about Chitosan, mainly addressing topics like pharmaceutical preparations, nanoparticles, evaluation studies and tissues. The most successful nations in the field of chitosan-related publications are again: China (74 articles), India (24) and USA (19).

Publications in February 2015

After an excellent start in January 2015, the number of chitosan-related articles slightly decreased in February. Scientific journals released 142 publications, which mainly focused on pharmaceutical preparations, nanoparticles and evaluation studies. Again, the three leading nations in chitosan research are China (40 articles), India (19) and USA (13). German scientists are placed among the top 10, as they contributed 5 reports.

Publications in January 2015

At the beginning of the year 2015, an incredible large number of chitosan-related articles have been released, indicating another record year. All in all, 196 publications about chitosan and its derivatives were contributed by scientist from all over the world, especially from China (46 articles), India (29) and USA (15). The main terms address chitosan in evaluation studies, nanoparticles and pharmaceutical preparations. 

Publications in March 2012

Overall 131 articles about chitosan and chitosan derivatives were published in March 2012.

As in the previous month, China is the country with the most publications with overall 35 articles, followed by the USA (14 articles), India (9 articles) and Taiwan (8 articles).

 

Publications in September 2010

Besides interesting conferences like the ESB Meeting (European Conference on Biomaterials) from September 11 to 15 in Tampere, Finland many international articles about the application of chitosan appeared. As usual, some interesting papers will be presented.

Nanoparticles: Trojan Horse for APIs

The big challenge in the field of medical innovations is so tiny that it is not noticeable with the naked eye. Nanotechnology – a promising and trendsetting technology. For example, with the help of drug-delivery-systems drugs can be transported to an exactly defined part within the body.
Chitosan also produces nanoparticles.

Veröffentlichungen im August 2010

Der Sommer neigt sich zum Ende – das heißt aber nicht, dass die News rund um Chitosan nicht heiß sind. Hier der Review der Chitosan Veröffentlichungen im August. 97 wissenschaftliche Artikel wurden veröffentlicht, in denen mit Chitosan gearbeitet wurde. Im Int J Biol Macromol wurden 8 Artikel veröffentlicht. Die Top drei Nationen bezogen auf die Anzahl der Artikel sind China, USA und Indien, gefolgt von Portugal auf Platz 4.

Publications in Chitosan Research in 2008

The systematic study on chitosan and its applications also significantly gains in importance in 2008. The number of articles mentioning chitosan in their title and published in biomedical journals rise by 46% compared to the number of 2007 publications. Exploratory focus of the 692 articles were mainly in the areas biotechnology and pharmaceuticals.

Congress and fairs

Meet us in person 2024:

  • 14th PBP World Meeting/ Research Pharm, Vienna, Austria, 18.-21.03.2024
  • EPNOE Workshop on Analytics of Polysaccharides, ETH Zürich, Zürich, Switzerland, 25.-26.06.2024
  • CPHI, Milan, Italy, 08.-10.10.2024
  • MEDICA 2024, Düsseldorf, Germany, 11.-14.11.2024

To arrange an appointment please contact Katja Richter via This email address is being protected from spambots. You need JavaScript enabled to view it.

Contact

  • Heppe Medical Chitosan GmbH
    Heinrich-Damerow-Strasse 1
    06120 Halle (Saale)
    Germany
  • Tel.: +49 (0) 345 27 996 300
    Fax: +49 (0) 345 27 996 378
  • This email address is being protected from spambots. You need JavaScript enabled to view it.
Contact | GTC / Terms of Use | Legal info | Copyright © 2024 Heppe Medical Chitosan GmbH | Privacy notice

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.